277 related articles for article (PubMed ID: 32727767)
1. Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy.
Kurokawa T; Hamai Y; Emi M; Ibuki Y; Yoshikawa T; Ohsawa M; Hirohata R; Okada M
Anticancer Res; 2020 Aug; 40(8):4387-4394. PubMed ID: 32727767
[TBL] [Abstract][Full Text] [Related]
2. Early Recurrence and Cancer Death After Trimodal Therapy for Esophageal Squamous Cell Carcinoma.
Hamai Y; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Furukawa T; Kurokawa T; Ohsawa M; Okada M
Anticancer Res; 2019 Mar; 39(3):1433-1440. PubMed ID: 30842179
[TBL] [Abstract][Full Text] [Related]
3. SUV
Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
[TBL] [Abstract][Full Text] [Related]
4. Predictions of Pathological Features and Recurrence Based on FDG-PET Findings of Esophageal Squamous Cell Carcinoma after Trimodal Therapy.
Hamai Y; Emi M; Ibuki Y; Murakami Y; Nishibuchi I; Nagata Y; Furukawa T; Kurokawa T; Ohsawa M; Yoshikawa T; Okada M
Ann Surg Oncol; 2020 Oct; 27(11):4422-4430. PubMed ID: 32405978
[TBL] [Abstract][Full Text] [Related]
5. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgery.
Hamai Y; Hihara J; Emi M; Furukawa T; Murakami Y; Nishibuchi I; Ibuki Y; Yamakita I; Kurokawa T; Nagata Y; Okada M
World J Surg; 2018 May; 42(5):1496-1505. PubMed ID: 29030675
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
[TBL] [Abstract][Full Text] [Related]
8. Comparison of long-term outcomes between esophagectomy and chemoradiotherapy after endoscopic resection of submucosal esophageal squamous cell carcinoma.
Tanaka T; Ueno M; Iizuka T; Hoteya S; Haruta S; Udagawa H
Dis Esophagus; 2019 Dec; 32(12):. PubMed ID: 30980070
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
[TBL] [Abstract][Full Text] [Related]
10. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
Lu SL; Hsu FM; Tsai CL; Lee JM; Huang PM; Hsu CH; Lin CC; Chang YL; Hsieh MS; Cheng JC
Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
[TBL] [Abstract][Full Text] [Related]
12. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
[TBL] [Abstract][Full Text] [Related]
13. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
[No Abstract] [Full Text] [Related]
14. Clinicopathological parameters predicting recurrence of pT1N0 esophageal squamous cell carcinoma.
Xue LY; Qin XM; Liu Y; Liang J; Lin H; Xue XM; Zou SM; Zhang MY; Zhang BH; Hui ZG; Zhao ZT; Ren LQ; Zhang YM; Liu XY; Yuan YL; Ying JM; Gao SG; Song YM; Wang GQ; Dawsey SM; Lu N
World J Gastroenterol; 2018 Dec; 24(45):5154-5166. PubMed ID: 30568392
[TBL] [Abstract][Full Text] [Related]
15. Survival benefits of adjuvant chemotherapy for patients with residual pathologic disease after neoadjuvant chemotherapy and surgery for locally advanced esophageal squamous cell carcinoma.
Lu H; Liu JF; Rong Y; Liu XB; Wang Y
J Gastrointest Surg; 2024 Jun; 28(6):867-869. PubMed ID: 38570232
[TBL] [Abstract][Full Text] [Related]
16. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes after non-curative endoscopic resection for esophageal squamous cell carcinoma followed by additional chemoradiotherapy.
Cho H; Abe S; Nonaka S; Suzuki H; Yoshinaga S; Okuma K; Yamamoto S; Daiko H; Kato K; Sekine S; Boku N; Saito Y
Dis Esophagus; 2024 Apr; 37(5):. PubMed ID: 38266034
[TBL] [Abstract][Full Text] [Related]
18. Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma.
Zhou N; Mitchell KG; Corsini EM; Truong VTT; Antonoff MB; Mehran RJ; Rajaram R; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Ajani JA; Hofstetter WL
Br J Surg; 2021 Oct; 108(10):1207-1215. PubMed ID: 34095952
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
20. Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy.
Oguma J; Ishiyama K; Kurita D; Kanematsu K; Kubo K; Utsunomiya D; Yamamoto S; Honma Y; Kato K; Daiko H
Esophagus; 2023 Apr; 20(2):215-224. PubMed ID: 36565340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
